What was the overall market valuation of the US stem cell-reconstructive market in 2024?

The overall market valuation was $362.19 Million in 2024. Read More

What is the projected market valuation for the US stem cell-reconstructive market by 2035?

The projected valuation for 2035 is $690.0 Million. Read More

What is the expected CAGR for the US stem cell-reconstructive market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.03%. Read More

Which company is a key player in the US stem cell-reconstructive market?

Key players include Athersys Inc, Osiris Therapeutics Inc, and Vericel Corporation. Read More

What are the main sources of stem cells in the US market?

The main sources include autologous cells valued at $189.42 Million in 2024 and projected to reach $360.0 Million. Read More

What types of stem cells are primarily used in the US stem cell-reconstructive market?

Adult stem cells accounted for $289.75 Million in 2024, with projections of $556.0 Million by 2035. Read More

What applications are driving growth in the US stem cell-reconstructive market?

Applications such as cancer treatment, valued at $72.44 Million in 2024, are expected to grow significantly. Read More

What are the end-user segments in the US stem cell-reconstructive market?

End-users include hospitals and research institutes, each valued at $145.0 Million in 2024. Read More

How do allogeneic and syngeneic stem cell sources compare in market valuation?

Allogeneic sources were valued at $72.44 Million in 2024, while syngeneic sources were at $54.33 Million. Read More

What is the potential for growth in the US stem cell-reconstructive market?

The market appears poised for growth, with a projected increase to $690.0 Million by 2035. Read More

US Stem Cell Reconstructive Market

US Stem Cell Reconstructive Market Research Report By Sources (Allogeneic, Autologous, Syngeneic, Other), By Cell Types (Embryonic Stem Cell, Adult Stem Cell), By Application (Cancer, Diabetes, Traumatic Skin Defect, Severe Burn) and By End Users (Hospital, Research Institutes) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.03%

2024 Market Size

$ 362.19 Million

2035 Market Size

$ 690 Million

Life Sciences ● Updated April 2026 Report ID: MRFR/LS/18499-HCR | Pages: 100 | Author: Nidhi Mandole, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY sources (USD Million)
  1. 4.1.1 allogeneic
  2. 4.1.2 syngeneic
  3. 4.1.3 autologous
  4. 4.1.4 others
2. 4.2 Pharmaceutical, BY cell types (USD Million)
  1. 4.2.1 embryonic stem cells
  2. 4.2.2 adult stem cells
3. 4.3 Pharmaceutical, BY application (USD Million)
  1. 4.3.1 cancer
  2. 4.3.2 severe burn
  3. 4.3.3 diabetes
  4. 4.3.4 traumatic skin defect
  5. 4.3.5 others
4. 4.4 Pharmaceutical, BY end-user (USD Million)
  1. 4.4.1 hospitals
  2. 4.4.2 research institutes
  3. 4.4.3 others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Athersys Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Mesoblast Ltd (AU)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Osiris Therapeutics Inc (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Cynata Therapeutics Ltd (AU)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Regenative Labs LLC (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 StemCells Inc (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Tissue Regenix Group PLC (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Vericel Corporation (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY SOURCES
3. 6.3 US MARKET ANALYSIS BY CELL TYPES
4. 6.4 US MARKET ANALYSIS BY APPLICATION
5. 6.5 US MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY SOURCES, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY SOURCES, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY CELL TYPES, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY CELL TYPES, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END-USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY SOURCES, 2025-2035 (USD Million)
  2. 7.2.2 BY CELL TYPES, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Stem Cell Reconstructive Market Segmentation

US Stem Cell Reconstructive Market By sources (USD Million, 2025-2035)

allogeneic
syngeneic
autologous
others

US Stem Cell Reconstructive Market By cell types (USD Million, 2025-2035)

embryonic stem cells
adult stem cells

US Stem Cell Reconstructive Market By application (USD Million, 2025-2035)

cancer
severe burn
diabetes
traumatic skin defect
others

US Stem Cell Reconstructive Market By end-user (USD Million, 2025-2035)

hospitals
research institutes
others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”